Adaptimmune and GlaxoSmithKline have expanded their strategic collaboration and licensing agreement for as many as five programs, including the lead NY-ESO TCR program. GSK has an option on the NY-ESO-1 program through clinical proof of concept and, on exercise, will assume full responsibility for the program.   Under the expanded agreement, the companies will accelerate the development of Adaptimmune’s NY-ESO therapy into studies in synovial sarcoma and will explore development in myxoid roun...